Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer
Eligibility Criteria
Inclusion Criteria: 1. The age is 18 to 75 years (including boundary values) and the gender is not limited; 2. Patients with advanced GI tumors diagnosed by pathohistology, mainly: (1)Patients with metastatic colorectal cancer who have failed or are intolerant to second-line and above standard therapy; Notes: 1. The standardized systemic treatment received by the patient must be in accordance with the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Treatment of Colorectal and Gastric Cancer, 2024 Edition; 2. Claims of treatment intolerance: Patients who are unable to continue current effective systemic standardized treatment due to toxic side effects such as grade ≥3 vomiting, diarrhea, abdominal pain, bone marrow suppression, etc., and who do not accept refusal for financial and personal reasons; 3.Presence of at least one measurable lesion that meets RECIST 1.1 criteria; 4.Patients must provide a tumor sample within 2 years that meets the requirements (paraffin block o